{"id":330365,"date":"2026-10-28T12:45:08","date_gmt":"2026-10-28T07:15:08","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=330365"},"modified":"2026-10-28T12:45:08","modified_gmt":"2026-10-28T07:15:08","slug":"global-generics-and-active-ingredients-maker-branded-formulations-company-and-research-led-pharma-company-stocks-roadmap-polaris-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/global-generics-and-active-ingredients-maker-branded-formulations-company-and-research-led-pharma-company-stocks-roadmap-polaris-list\/","title":{"rendered":"3 Global Generics and Active Ingredients Maker, Branded Formulations Company and Research-Led Pharma Company Stocks With a Strong Future Roadmap: Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals"},"content":{"rendered":"

Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals: ROE of 11.1% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 12.3%. Prices as of 27 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three international generics and formulation stocks to watch are Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals. Their return on equity ranges from 11.1% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 12.3%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Dr. Reddy’s Laboratories has the fastest revenue growth at 12.3% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

International generics and formulation stocks let investors follow companies that serve a growing part of the Indian economy. Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals cover a global generics and active ingredients maker, a branded formulations company and a research-led pharma company.<\/p>\n

This list covers three international generics and formulation stocks with complete current figures: Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n